Counterfeit Healthcare Products: Nepal at a Vulnerable Position.
Journal
JNMA; journal of the Nepal Medical Association
ISSN: 1815-672X
Titre abrégé: JNMA J Nepal Med Assoc
Pays: Nepal
ID NLM: 0045233
Informations de publication
Date de publication:
01 Dec 2022
01 Dec 2022
Historique:
received:
17
07
2022
accepted:
28
10
2022
entrez:
27
1
2023
pubmed:
28
1
2023
medline:
31
1
2023
Statut:
epublish
Résumé
Nepal stands in a vulnerable position when it comes to counterfeit medicines as two of its major trade partners countries are leading producers of falsified healthcare products. The impacts that it can lead to are a lower standard of healthcare delivery to the public, increased cost of treatment, antibiotic resistance, and even fatality. The time of crisis as the Coronavirus disease 2019 pandemic is often seen as an opportunity to endorse substandard products in greater amounts. The people's doubt over the medicine is another issue generated by this malpractice that can lead to problems like vaccine hesitancy which can have scary outcomes so forth in a pandemic situation like this. Stronger national policies and vigilant authorities are prime to overcoming flourishing counterfeit culture as it is a peak time when we can not put public health at stake. counterfeit medicines; Nepal; patient safety; substandard medicines.
Identifiants
pubmed: 36705113
doi: 10.31729/jnma.7684
pmc: PMC9795120
doi:
Substances chimiques
Counterfeit Drugs
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1070-1072Références
J Nepal Health Res Counc. 2015 Sep-Dec;13(31):233-40
pubmed: 27005718
JAMA Netw Open. 2018 Aug 3;1(4):e181662
pubmed: 30646106